ARTERIUS

Commencing research in November 2010, Leeds-based Arterius is developing ArterioSorb™, a next-generation bioabsorbable (BRS) stents with an emerging market-leading clinical profile. ArterioSorb has the thinnest profile of any cardiovascular stent at 95 microns, and has a world leading 80-micron stent in in-vitro trials. The company requires a tranched investment of up to £6m over the next three years to bring this product through first in man; CE Mark trials and an early exit for the coronary stent business shortly thereafter. The company is also developing bioresorbable peripheral stent, and other BRS products.